These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 34692515)
1. SUZ12 Loss Amplifies the Ras/ERK Pathway by Activating Adenylate Cyclase 1 in NF1-Associated Neurofibromas. Li W; Hu C; Zhang X; Wang B; Li Z; Ling M; Sun S; Guo C; Li D; Liu S Front Oncol; 2021; 11():738300. PubMed ID: 34692515 [TBL] [Abstract][Full Text] [Related]
3. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions. Mußotter T; Kluwe L; Högel J; Nguyen R; Cooper DN; Mautner VF; Kehrer-Sawatzki H BMC Med Genet; 2012 Oct; 13():98. PubMed ID: 23101500 [TBL] [Abstract][Full Text] [Related]
4. Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197 [TBL] [Abstract][Full Text] [Related]
6. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341 [TBL] [Abstract][Full Text] [Related]
7. TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions. Park GH; Lee SJ; Yim H; Han JH; Kim HJ; Sohn YB; Ko JM; Jeong SY Oncol Rep; 2014 Oct; 32(4):1347-54. PubMed ID: 25109740 [TBL] [Abstract][Full Text] [Related]
9. Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST. Lu HC; Eulo V; Apicelli AJ; Pekmezci M; Tao Y; Luo J; Hirbe AC; Dahiya S Oncotarget; 2018 May; 9(33):23018-23028. PubMed ID: 29796169 [TBL] [Abstract][Full Text] [Related]
10. Transposon Mutagenesis-Guided CRISPR/Cas9 Screening Strongly Implicates Dysregulation of Hippo/YAP Signaling in Malignant Peripheral Nerve Sheath Tumor Development. Vélez-Reyes GL; Koes N; Ryu JH; Kaufmann G; Berner M; Weg MT; Wolf NK; Rathe SK; Ratner N; Moriarity BS; Largaespada DA Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33808166 [TBL] [Abstract][Full Text] [Related]
11. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697 [TBL] [Abstract][Full Text] [Related]
12. Emerging genotype-phenotype relationships in patients with large NF1 deletions. Kehrer-Sawatzki H; Mautner VF; Cooper DN Hum Genet; 2017 Apr; 136(4):349-376. PubMed ID: 28213670 [TBL] [Abstract][Full Text] [Related]
13. The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors. Kraniak JM; Sun D; Mattingly RR; Reiners JJ; Tainsky MA Mol Cell Biochem; 2010 Nov; 344(1-2):267-76. PubMed ID: 20680410 [TBL] [Abstract][Full Text] [Related]
14. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene. Friedrich RE; Kluwe L; Fünsterer C; Mautner VF Anticancer Res; 2005; 25(3A):1699-702. PubMed ID: 16033085 [TBL] [Abstract][Full Text] [Related]
15. Deregulated expression of polycomb repressive complex 2 target genes in a NF1 patient with microdeletion generating the RNF135-SUZ12 chimeric gene. Tritto V; Grilli F; Milani D; Riva P Neurogenetics; 2023 Jul; 24(3):181-188. PubMed ID: 37145209 [TBL] [Abstract][Full Text] [Related]
16. Association between benign and malignant peripheral nerve sheath tumors in NF1. Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787 [TBL] [Abstract][Full Text] [Related]
17. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448 [TBL] [Abstract][Full Text] [Related]
18. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings. Spurlock G; Knight SJ; Thomas N; Kiehl TR; Guha A; Upadhyaya M J Cancer Res Clin Oncol; 2010 Dec; 136(12):1869-80. PubMed ID: 20229272 [TBL] [Abstract][Full Text] [Related]
19. The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis. Luscan A; Shackleford G; Masliah-Planchon J; Laurendeau I; Ortonne N; Varin J; Lallemand F; Leroy K; Dumaine V; Hivelin M; Borderie D; De Raedt T; Valeyrie-Allanore L; Larousserie F; Terris B; Lantieri L; Vidaud M; Vidaud D; Wolkenstein P; Parfait B; Bièche I; Massaad C; Pasmant E Clin Cancer Res; 2014 Jan; 20(2):358-71. PubMed ID: 24218515 [TBL] [Abstract][Full Text] [Related]
20. Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST. Prieto-Granada CN; Wiesner T; Messina JL; Jungbluth AA; Chi P; Antonescu CR Am J Surg Pathol; 2016 Apr; 40(4):479-89. PubMed ID: 26645727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]